Literature DB >> 9239414

Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites.

J C López-Talavera1, A Levitzki, M Martínez, A Gazit, R Esteban, J Guardia.   

Abstract

Tumor necrosis factor-alpha (TNF) causes vasodilatation and a hyperdynamic state by activating nitric oxide (NO) synthesis. Tyrphostins, specific inhibitors of protein tyrosine kinase (PTK), block the signaling events induced by TNF and NO production. A hyperdynamic circulatory syndrome (HCS) is often observed in portal hypertension (PHT). TNF and NO seem to mediate these hemodynamic changes. The aim of this work was to study the effect of PTK inhibition on the systemic and portal hemodynamics, TNF and NO production, in cirrhotic rats with portal hypertension. Rats with liver cirrhosis induced by chronic inhalation of carbon tetrachloride were used. Animals were treated daily with tyrphostin AG 126 (alpha-cyano-(3-hydroxy-4-nitro) cinnamonitrile) or placebo for 5 d. Mean arterial pressure (MAP), heart rate (HR), and portal pressure (PP) were measured by indwelling catheters. Cardiac output (CI) and stroke volume (SV) were estimated by thermodilution, systemic vascular resistance (SVR) was calculated (MAP/CI), and portal systemic shunting (PSS) was quantitated using radioactive microspheres. Serum and mesenteric lymph node (MLN) TNF levels were measured using an immunoassay kit, and serum NOx was determined photometrically by its oxidation products. The AG 126-treated group showed a statistically significant increase in MAP and SVR, and decreases in CI, SV, MLN TNF, and serum NO oxidation products nitrite and nitrate (NOx) in comparison with the placebo-treated rats. No significant differences were noticed in HR, PP, PSS, or serum TNF. Significant correlations were observed between MAP and NOx, MAP and MLN TNF, PSS and NOx, and serum TNF and serum NOx. The HCS observed in PHT seems to be mediated, at least in part, by TNF and NO by the activation of PTKs and their signaling pathways. PTK activity inhibition ameliorates the hyperdynamic abnormalities that characterize animals with cirrhosis and PHT.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9239414      PMCID: PMC508235          DOI: 10.1172/JCI119578

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo.

Authors:  M Fràter-Schröder; W Risau; R Hallmann; P Gautschi; P Böhlen
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

Review 2.  Pathogenetic mechanisms of septic shock.

Authors:  J E Parrillo
Journal:  N Engl J Med       Date:  1993-05-20       Impact factor: 91.245

3.  Tumor necrosis factor causes increased pulmonary permeability and edema. Comparison to septic acute lung injury.

Authors:  K E Stephens; A Ishizaka; J W Larrick; T A Raffin
Journal:  Am Rev Respir Dis       Date:  1988-06

Review 4.  Cytokines of the lung.

Authors:  J Kelley
Journal:  Am Rev Respir Dis       Date:  1990-03

5.  Tumor necrosis factor alpha production by peripheral blood mononuclear cells of patients with chronic liver disease.

Authors:  K Yoshioka; S Kakumu; M Arao; Y Tsutsumi; M Inoue
Journal:  Hepatology       Date:  1989-11       Impact factor: 17.425

6.  Portal-systemic shunting and the hemodynamic effects of nitroglycerin in the rat.

Authors:  A T Blei; D J O'Reilly; J Gottstein
Journal:  Gastroenterology       Date:  1984-06       Impact factor: 22.682

7.  Tumor necrosis factor (TNF).

Authors:  L J Old
Journal:  Science       Date:  1985-11-08       Impact factor: 47.728

8.  Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor.

Authors:  J R Gamble; J M Harlan; S J Klebanoff; M A Vadas
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

9.  Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats.

Authors:  C C Sieber; J C Lopez-Talavera; R J Groszmann
Journal:  Gastroenterology       Date:  1993-06       Impact factor: 22.682

10.  Bacterial translocation in acute and chronic portal hypertension.

Authors:  G Garcia-Tsao; A Albillos; G E Barden; A B West
Journal:  Hepatology       Date:  1993-06       Impact factor: 17.425

View more
  4 in total

Review 1.  The hepatorenal syndrome.

Authors:  L Dagher; K Moore
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

Review 2.  Infection, coagulation, and variceal bleeding in cirrhosis.

Authors:  U Thalheimer; C K Triantos; D N Samonakis; D Patch; A K Burroughs
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

3.  Adrenomedullin, a vasodilator peptide implicated in hemodynamic alterations of liver cirrhosis: relationship to nitric oxide.

Authors:  J Genesca; A Gonzalez; R Catalan; R Segura; M Martinez; R Esteban; R J Groszmann; J Guardia
Journal:  Dig Dis Sci       Date:  1999-02       Impact factor: 3.199

4.  Increased tumour necrosis factor alpha production in mesenteric lymph nodes of cirrhotic patients with ascites.

Authors:  J Genescà; R Martí; F Rojo; F Campos; V Peribáñez; A Gónzalez; L Castells; C Ruiz-Marcellán; C Margarit; R Esteban; J Guardia; R Segura
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.